Anti-DR5Antibody
CatalogNo.:2421
Size:100ugIgGinPBS,pH7.4,purifiedbyimmunoaffinitychromatography.
ApoptosisisinducedbycertaincytokinesincludingTNFandFasligandintheTNFfamilythroughtheirdeathdomain-containingreceptors.TRAIL/Apo2LisanewmemberoftheTNFfamily.Anoveldeathdomain-containingreceptorforTRAILwasrecentlyidentifiedanddesignatedDR5,Apo2,
TRAIL-R2,TRICK2,orKILLERbyseveralindependentlaboratories.LikeDR4,DR5transcriptiswidelyexpressedinnormaltissuesandinmanytypesoftumorcells.DR5bindstoTRAILandmediatesTRAIL-inducedcelldeath.OverexpressionofDR5inducesapoptosisandactivatesNF-B.
Antigen:Peptidecorrespondingtoaa388-407ofhumanDR5precursor(accessionno.AF012535).
HostSpecies:Rabbit
StABIlizers:None
Preservatives:0.02%sodiumazide.
Thisantibodyrecognizesfull-lengthhumanandmouseDR5(57kDa).
APPLICATIONSImmunoblotting:useat2ug/ml.
WesternblotanalysisofDR5inHeLa(H)andK562(K)celllysateswithDR5antibodyat2g/ml.
Positivecontrol:WholecelllysatefromHeLacellsorK562cells.
Immunocytochemistry:useat5ug/ml.
ImmunocytochemicalstainingofDR5inHeLacellswithDR5antibodyat5μg/ml.
Thesearerecommendedconcentrations.Endusershoulddetermineoptimalconcentrationsfortheirapplications.
DiluteinPBSormediumwhichisidenticaltothatusedintheassaysystem.
Thisantibodyisstableforatleastone(1)yearat-20oC.Avoidmultiplefreeze-thawcycles.
Forinvitroinvestigationaluseonly.Notforuseintherapeuticordiagnosticprocedures.
